The UK’s Chlordiazepoxide shortage: What it means for alcohol detox and how to navigate it safely

On 30 March 2026, the Department of Health and Social Care issued Medicine Supply Notification MSN/2026/02, a Tier 2 alert confirming that chlordiazepoxide 5mg and 10mg capsules manufactured by Viatris are out of stock until at least mid-July 2026. In the same notification, DHSC confirmed that Kent Pharma has discontinued its 10mg capsules entirely and will discontinue its 5mg capsules from 31 March 2026. While Crescent Pharma retains some stock, the supply of its 5mg capsules is insufficient to meet full demand.

This is not an isolated manufacturing hiccup. It is the latest and among the most clinically consequential manifestation of a medicines supply crisis that a July 2025 All Party Parliamentary Group on Pharmacy inquiry described as having shifted from isolated incidents to a chronic, structural challenge.

For those of us working at the coalface of addiction treatment, this supply disruption arrives at the worst possible moment.

A record-breaking toll

The UK is drinking itself to death at historically unprecedented rates. Office for National Statistics data published in February 2025 recorded 10,473 alcohol-specific deaths across the UK in 2023 the highest annual figure since records began in 2001, representing a 38% increase from the pre-pandemic year of 2019. The Office for Health Improvement and Disparities reported 8,274 alcohol-specific deaths in England alone in 2023, a rate ofl5.0 per 100,000-the highest since the data series began in 2006, representing a 63.8% increase over that period. More recent data from the Institute of Alcohol Studies indicates that in 2024, 7,673 people died in England from alcohol-specific causes alone.

Behind these figures lies a treatment system under extraordinary pressure. According to the National Drug Treatment Monitoring System, only an estimated 22.4% of the 608,416 people with alcohol dependence in England are currently accessing treatment. New presentations for alcohol treatment have risen 34% between 2020/21 and 2024/25 the highest number since records began in 2005/06.

Against this backdrop, restricting access to the frontline medication used to safely detoxify these patients is not merely inconvenient. It is potentially catastrophic.

Why Chlordiazepoxide matters

Chlordiazepoxide, marketed under the brand name Librium, occupies a unique and critical position in the management of alcohol dependence in the UK. NICE Clinical Guideline 115 recommends either chlordiazepoxide or diazepam for medically assisted alcohol withdrawal, but chlordiazepoxide has long been the preferred agent in community settings for important clinical reasons.

The Northern Ireland Formulary states the rationale clearly: chlordiazepoxide is the first-choice oral agent for outpatient and general practice alcohol withdrawal because it has less abuse potential and lower street value than diazepam. This matters enormously when prescribing to a population already vulnerable to substance misuse in settings where daily clinical supervision is not always feasible.

Chlordiazepoxide also has a pharmacological profile well-suited to managing withdrawal. Its relatively long half-life produces a smoother, more predictable tapering of symptoms compared with shorter-acting alternatives. The vast majority of community detoxification protocols across UK NHS trusts have been designed around chlordiazepoxide dosing regimens standardised, familiar, and well understood by GPs and addiction services alike.

When that medication becomes unavailable across multiple manufacturers simultaneously, the consequences are far-reaching.

What the shortage means in practice

The DHSC notification reveals a supply picture that is more precarious than previous chlordiazepoxide shortages. This is not a single-manufacturer problem with ready alternatives: Viatris stock is depleted until mid-July 2026, Kent Pharma has exited the market entirely, and Crescent’s residual supply cannot meet national demand.

Community Pharmacy England has circulated the MSN to all pharmacy NHS email addresses, and the DHSC Medicines Supply Tool has been updated accordingly. But for clinicians and patients navigating the coming weeks, the practical implications are serious.

• Delayed treatment initiation. Patients presenting for community detoxification may face waits while pharmacies attempt to source remaining stock, during which time they may continue drinking or far worse attempt to stop abruptly without medical support. Alcohol withdrawal is one of the very few substance withdrawal syndromes that can be directly fatal, progressing to delirium tremens, seizures, and death.
• Unfamiliar substitutions and prescribing risk. Clinicians who have prescribed chlordiazepoxide for years will be forced to switch to alternatives with different pharmacological profiles, dosing schedules, and risk profiles. NHS Greater Glasgow and Clyde’s guidance during a previous chlordiazepoxide shortage in 2014 noted that switching protocols required recalculation of dosing regimens, new patient education, and increased monitoring intensity -all placing additional demands on already-stretched services.
• Increased diversion risk with diazepam. The most common substitute, diazepam, has a significantly higher abuse potential and street value. The British National Formulary equivalence is approximately 5mg diazepam to 12.5mg chlordiazepoxide. NHS guidelines recommend that when diazepam is used in community alcohol detox, instalment dispensing should be considered with no more than two days’ medication available at a time a safeguarding measure that adds substantial operational burden.
• Fragmented care pathways. Patients may need to attend multiple pharmacies, experience mid-detox medication changes, or face delays at a moment when continuity and consistency are critical to safe withdrawal management.

The alternatives: Clinical considerations

When chlordiazepoxide is unavailable, there are pharmacological alternatives – but none are straightforward substitutions. Each carries trade-offs that must be carefully weighed against the individual patient’s clinical profile.

• Diazepam is licensed for use as an adjunct in acute alcohol withdrawal and is the most widely used alternative. However, its longer and less predictable half-life (20-100 hours, compared with chlordiazepoxide’s 5-30 hours) due to active metabolites requires careful monitoring. Its higher abuse potential necessitates restricted dispensing in community settings.
• Lorazepam is the preferred option in patients with significant liver impairment, as it undergoes glucuronidation rather than hepatic oxidation and produces no active metabolites. NHS Greater Glasgow and Clyde guidelines recommend lorazepam for patients with clinical evidence of liver disease, especially jaundice or encephalopathy. However, its shorter duration of action requires more frequent dosing and carries a greater risk of rebound withdrawal symptoms.
• Oxazepam offers similar hepatic safety advantages to lorazepam and is sometimes used for older adults, patients with respiratory conditions, or those at risk of over-sedation. Like lorazepam, it requires more frequent dosing than chlordiazepoxide.

In every case, switching demands a comprehensive clinical reassessment. Previous NHS trust guidance during chlordiazepoxide shortages has emphasised that the decision must account for the patient’s severity of alcohol dependence (SADQ score), liver function, nutritional status, physical and psychological co-morbidities, and previous detox history. This is emphatically not a pharmacy-level substitution it requires specialist prescriber oversight.

The wider crisis: Systemic fragility

This shortage exists within a broader pattern of medicines supply failure that has become a defining feature of UK healthcare in recent years. The House of Commons Library research briefing on medicines shortages (CBP-9997), updated on 30 March 2026, documents a crisis driven by manufacturing problems, raw material shortages, increased demand, and what the British Generic Manufacturers Association has described as regulatory bottlenecks at the MHRA taking up to two-and-a-half years to approve routine licensing changes.

The government’s August 2025 paper, Managing a Robust and Resilient Supply of Medicines, acknowledged that while it cannot prevent all shortages, it would work to reduce their frequency and minimise patient impact. Proposals include consulting on “pharmacist flexibilities” to allow community pharmacists to supply alternative strengths or formulations. These are welcome steps but they are not sufficient for medications used in acute, time-critical, and potentially life-threatening clinical scenarios.

The estimated cost of alcohol harm in England alone was £27.44 billion per year in 2024, according to the Institute of Alcohol Studies. When the medication that enables safe detoxification becomes unavailable, the downstream costs in emergency department attendances, ICU admissions, coroner’s inquests, and human lives are incalculable.

How Harbor navigates this challenge

At Harbor, we have always maintained that effective addiction treatment demands clinical agility the capacity to adapt safely and without compromise to whatever the pharmaceutical landscape demands.

Our medically supervised detoxification programmes are led by a multidisciplinary team of consultant psychiatrists, physicians, therapists, and specialist nurses who collaborate to design individualised treatment plans for every patient. This means we are never reliant on a single prescribing protocol. When supply disruptions affect a particular agent, we have the clinical depth and prescribing flexibility to identify the safest alternative for each individual patient – taking full account of their drinking history, liver function, co-morbidities, previous detox experiences, and personal recovery goals.

Our one-client-at-a-time model is particularly valuable in this context. Unlike services managing large caseloads with standardised prescribing, our approach allows the pharmacological management of withdrawal to be tailored to precise individual needs with continuous medical oversight that can respond immediately to any clinical change.

Having worked in this field for over 30 years training at The Maudsley Hospital, serving as Associate Medical Director within the NHS, advising the Civil Aviation Authority, and presenting on addiction at international conferences and the House of Lords. I have navigated previous medication shortages and understand the clinical risks they introduce. It is the combination of deep specialist expertise with the flexibility of a bespoke, consultant-led treatment model that allows Harbor to maintain the highest standard of care regardless of supply chain disruption.

What patients and families should know

If you or someone you care about is considering alcohol detoxification, there are several things to keep in mind as this shortage unfolds.

• Do not attempt to detox from alcohol without medical supervision. The risks of unmanaged withdrawal are too severe. Even if your usual GP is unable to prescribe chlordiazepoxide due to supply issues, there are safe alternatives but they must be prescribed and monitored by a clinician with appropriate expertise.
• Seek specialist advice early. Addiction services whether NHS community teams or private providers like Harbor can assess your individual needs and identify the safest pharmacological approach given current availability. The earlier this conversation happens, the more options remain available.
• Understand that medication is only one component of recovery. Effective detoxification must be accompanied by a comprehensive care plan that includes psychosocial support, nutritional rehabilitation, thiamine and vitamin B supplementation to prevent Wernicke’s encephalopathy, and a clear pathway into ongoing treatment and relapse prevention. At Harbor, we build this holistic framework around every individual from the outset.

A call to action

A shortage of a medication used to treat hypertension is concerning. A shortage of a medication used to prevent fatal withdrawal seizures at a time when alcohol-specific deaths are at their highest recorded level is unconscionable.

We need faster regulatory pathways at the MHRA for approving alternative suppliers. We need a more robust early-warning system for shortages affecting medications used in acute, time-critical clinical settings. We need greater investment in domestic pharmaceutical manufacturing capacity. And we need to ensure that the voices of patients with addiction, already among the most marginalised and underserved in our healthcare system, are heard in the policy discussions that will shape the UK’s medicines supply for decades to come.

If you are concerned about your alcohol use or that of someone close to you, Harbor London is here to help. Our team provides confidential, medically led assessment and treatment, with the specialist expertise to navigate the current supply landscape safely and effectively.

To speak with a member of our team in confidence, visit  harborlondon.com or call us directly. Your recovery should never be delayed by a supply chain failure.

References:

• DHSC Medicine Supply Notification MSN/2026/021, 30 March 2026 – Chlordiazepoxide 5mg and 10mg capsules (Tier 2 – Medium Impact)
• Community Pharmacy England – Medicine Supply Notification: Chlordiazepoxide 5mg and 10mg capsules, 30 March 2026
• Office for National Statistics – Alcohol-specific deaths in the UK: registered in 2023, published 5 February 2025
• Office for Health Improvement and Disparities – Alcohol Profi.le: Short Statistical Commentary, February 2025
• Institute of Alcohol Studies – Health Factsheet, updated 2025
• National Drug Treatment Monitoring System (NDTMS) – Adult Substance Misuse Treatment Statistics, 2024/25
• House of Commons Library – Research Briefing: Medicines Shortages (CBP-9997), updated 30 March 2026
• All Party Parliamentary Group on Pharmacy – Inquiry Report: Medicines Shortages in England, July 2025
• DHSC – Managing a Robust and Resilient Supply of Medicines, August 2025
• NICE Clinical Guideline CG115 – Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence
• Northern Ireland Formulary – Section 4.10.4.1: Acute Alcohol Withdrawal
• NHS Greater Glasgow and Clyde – Management ofAlcohol Withdrawal Syndrome; Chlordiazepoxide Guidance During Shortage, September 2014
• NHS England – Adult Psychiatric Morbidity Survey: Survey of Mental Health and Wellbeing, England, 2023/24
• Journal of Medical Toxicology- Benzodiazepine Shortages: A Recurrent Challenge in Need of a Solution (2022)